ArticleJournal of orthopaedic surgery and research2026
Multi-omics Mendelian randomization prioritizes BMP6 as a candidate therapeutic target in intervertebral disc degeneration.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIntervertebral disc degeneration (IVDD) is a prevalent condition causing substantial pain, muscle weakness, and functional impairment; however, the efficacy of current treatments remains limited. Therefore, candidate therapeutic targets must urgently be prioritized to guide future mechanistic and translational research. This study aims to identify genetic factors associated with IVDD and explore the underlying mechanisms through the comprehensive integration of multi-omics data.
methodsWe applied Mendelian randomization (MR) to prioritize candidate therapeutic genetic targets for IVDD using genome-wide summary statistics from the FinnGen consortium, with UK Biobank data serving as replication cohorts. We employed expression quantitative trait loci (eQTLs) and protein quantitative trait loci (pQTLs) to validate therapeutic targets at the transcriptomic and proteomic levels. We also integrated sensitivity, colocalization, SMR, genetic correlation, and reverse MR analyses. We applied PheWAS and drug prediction to assess off-target effects and evaluate therapeutic potential, respectively. Finally, we explored the potential mediation effects of candidate metabolites.
resultsWe identified seven potential therapeutic targets significantly associated with IVDD risk across the FinnGen and UK Biobank cohorts. Bayesian colocalization analysis revealed strong evidence for shared causal variants at the DLK1 (PP.H4 = 0.94) and BMP6 (PP.H4 = 0.99) loci. The BMP6 cis-eQTL met the significance thresholds for SMR (p < 0.05) and HEIDI (p > 0.05). Protein-level MR analysis demonstrated that BMP6 significantly increased IVDD risk (OR = 1.19, 95% CI 1.09-1.30; p < 0.001), supported by a colocalization probability of 99% (PP.H4 = 0.99). Additionally, BMP6 satisfied the established validation thresholds in protein-level SMR and HEIDI analyses. Consequently, BMP6 was prioritized as a candidate therapeutic target for IVDD in subsequent analyses. Urate levels exhibited a nominal mediation signal linking BMP6 to IVDD (proportion mediated = 7.48%, p = 0.036), which remained suggestive after BH-FDR correction.
conclusionsWe prioritized BMP6 as a candidate therapeutic target for IVDD and identified circulating urate as a potential mediator based on a suggestive mediation signal. These findings offer new mechanistic insights into the potential relationship between BMP6, urate metabolism, and IVDD. This gene and its associated metabolite represent promising targets for IVDD intervention and may inform subsequent translational research and preclinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.